Apellis Pharmaceuticals, Inc. faces a Sell rating amid revenue stagnation, Syfovre challenges, and uncertain long-term profit ...

Since an investor revolt early this year at Air Products and Chemicals, the new leadership at the industrial gas giant has ...

Several headwinds have pushed Regeneron 's (NASDAQ: REGN) shares lower over the past year and a half. However, the company is ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Regeneron Pharmaceuticals earns the No. 76 rank among its peers in the Medical-Biomed/Biotech industry group. Exact Sciences ...

Broadcom stock plunges as lower-margin AI revenue pressures profitability despite strong earnings and a record $73B backlog.